Related Experiment Video
Updated: May 16, 2026
07:23
Assessment of Morphine-induced Hyperalgesia and Analgesic Tolerance in Mice Using Thermal and Mechanical Nociceptive Modalities
Published on: July 29, 2014
Pharmacogenomic considerations in opioid analgesia
Pascal H Vuilleumier1, Ulrike M Stamer, Ruth Landau
1Klinik für Anästhesiologie und Schmerztherapie, Inselspital Universität Bern, Switzerland;
Pharmacogenomics and Personalized Medicine
|December 11, 2012
Summary
Pharmacogenetics shows promise for predicting opioid response, but clinical application for pain management remains complex. Genetic testing for CYP2D6 and CYP3A4 may inform oxycodone therapy, though morphine response prediction is less clear.
Area of Science:
- Pharmacogenetics
- Pain Management
- Clinical Pharmacology
Background:
- Translating pharmacogenetics into clinical practice for pain management is challenging due to pain's complex, subjective nature.
- Numerous genes influence opioid pharmacokinetics and pharmacodynamics, making them candidates for predicting analgesic response.
- The clinical utility of genetic testing for opioid analgesia is still under investigation.
Purpose of the Study:
- To explore the challenges and current evidence regarding the translation of pharmacogenetics into clinical practice for pain management.
- To assess the role of genetic variability in predicting patient response to opioid analgesics, specifically oxycodone and morphine.
Main Methods:
- Review of existing evidence on gene polymorphisms (CYP2D6, CYP3A4) and their association with opioid response.
- Analysis of the complexity of pain perception and analgesic response influenced by genetic and non-genetic factors.
Main Results:
- Strong evidence links CYP2D6 and CYP3A4 genetic variability to oxycodone response and metabolism, but no randomized trials support pre-therapy genetic testing.
- CYP2D6 genotype extremes (ultrarapid and poor metabolism) may predict pain response or adverse effects.
- Predicting morphine analgesic response via pharmacogenetics is complex and unlikely to be simplified by basic genetic testing.
Conclusions:
- While pharmacogenetics offers insights into opioid analgesia, its direct clinical application for tailoring pain management is limited by complexity and lack of definitive trials.
- Genetic variability significantly impacts pain perception and response to analgesics, but factors like pain type, opioid choice, and administration route also play crucial roles.
Related Concept Videos
01:25Analgesia and Pain Management
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
01:20Opioid Analgesics: Morphine and Other Natural Cogeners
Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
01:15Opioid Analgesics: Synthetic and Semisynthetic Opioids
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
01:22Opioid Receptors: Overview
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2, D-Pen5]-enkephalin or DPDPE for...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...